A clinical trial by Boehringer Ingelheim Pharmaceuticals has begun that will evaluate the effects of Ofev on specific blood biomarkers in idiopathic pulmonary fibrosis patients.
Boehringer Ingelheim Pharmaceuticals recently began a clinical trial to assess the effect of Ofev (nintedanib) on specific blood biomarkers that may identify greater fibrosis and loss of lung function in patients with idiopathic pulmonary fibrosis (IPF).
Biomarkers are measurable indicators of some biological state or condition that help predict disease prognosis. The INMARK trial will measure biomarkers that reflect substances related with extracellular matrix (ECM) turnover — part of healthy tissue maintenance.
But excessive or uncontrolled turnover motivates the structural change seen in the lungs of patients with IPF, and that leads to progressive scarring and loss of lung function.
By evaluating baseline changes and values, it may be possible to determine patients with most active fibrosis, and determine the response to Ofev treatment. Additionally, correlating biomarker concentrations with final lung function assessments may identify early predictors for pulmonary progression.